COGT 240517 17.50C (COGT240517C17500) 股票期权、新闻、报价

自选
模拟交易
选股器
热力图
机构追踪

美股期权个股详情

COGT240517C17500

添加自选

0.55
0.000.00%

延时15分钟行情收盘价 02/14 12:45 (美东)

0.00最高价0.00最低价

分时

5日
日K

新闻

Trytosaveabit

17分钟前

Update

$Cogent Biosciences(COGT.US)$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile

Stock Region

02/24 00:35

Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company

Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...

Trytosaveabit

02/23 04:01

Sorry a bit late! Grrrr! Was busy! Grrrr

$Cogent Biosciences(COGT.US)$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago

JuliaBiswas

02/22 15:49

$Cogent Biosciences(COGT.US)$ new data is comin for mastocytosis, the presentation is scheduled at AAAAI conference in a couple of days. And bezuclastinib soon will be a new standard of care for GIST.

Meltyy

01/24 17:25

Ph2 readouts in Q1 2024...

$辉瑞(PFE.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...

COGT240517C17500

新闻

评论